GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy
GNT Pharma Inc. today reports positive top-line results from a phase II, double-blind, randomized, placebo-controlled, multi-center study assessing the safety and efficacy of nelonemdaz in acute ischemic stroke patients treated with endovascular thrombectomy within 8 hours of symptom onset (SONIC). In this study, the addition of nelonemdaz to surgical blood clot removal improved a patient’s chances of returning to functional independence 90 days later.
Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China.
SONIC enrolled 209 moderate to severe ischemic stroke patients (NIH Stroke Scale of 8 or higher) at 7 university stroke centers in South Korea. Patients received a 1st infusion of placebo, 500 mg nelonemdaz (low dose group), or 750 mg nelonemdaz (high dose group) prior to thrombectomy. Low dose and high dose groups then received 9 follow-up infusions of 250 mg and 500 mg nelonemdaz, respectively, at 12 hour intervals. The primary outcome was the fraction of patients with good functional outcome (no more than slight disability, able to look after own affairs without assistance) 90 days later, defined as a score of 0-2 on the modified Rankin Scale (mRS), the most widely used outcome measure in stroke studies. In the low dose nelomendaz group, 33 of 55 patients (60.0%) group achieved good functional outcome, and in the high dose nelomendaz group, 31 of 49 patients (64.6%) achieved good functional outcome, compared to 25 of 49 patients (51.0%) in the placebo group. The fraction of patients achieving near-complete recovery (mRS score 0) was markedly increased in nelonemdaz-treated groups, with 23.6% of the low dose group and 33.3% of the high dose group achieving no significant disability 90 days later, compared to only 8.2% of the placebo group. No serious adverse events of nelonemdaz were observed.
“Compared to placebo, administration of nelonemdaz increased the chances of achieving a good functional outcome by more than 20% in moderate to severe ischemic stroke patients who received endovascular thrombectomy”, said Dr. Byoung Joo Gwag, CEO and founder of GNT Pharma and inventor of nelonemdaz. “And it more than tripled chances of achieving a near-complete recovery. Over the last 3 decades, many NMDA antagonists and antioxidant drugs have failed in clinical stroke trials, despite showing efficacy in animal models of stroke. Such failed trials were probably due to the adverse effects of subtype-unselective NMDA receptor antagonists, or the limitations of targeting single injury mechanisms. SONIC was the first clinical trial of our novel multitarget neuroprotectant, nelonemdaz, administered to ischemic stroke patients who also received endovascular recanalization, which has recently become a standard of stroke care.”
Dr. Dennis W. Choi, a professor of neurology at the State University of New York, Stony Brook, a pioneer in the stroke neuroprotection field, and a scientific advisor to GNT Pharma, commented “these are very encouraging phase II results that heighten interest in seeing the results of larger phase III trials.”
In a companion phase II study with 237 acute ischemic stroke patients conducted in China, nelonemdaz was well tolerated and benefitted patients who were treated with thrombolytic drugs within 8 hours of symptom onset. A phase III study of nelonemdaz for 948 ischemic stroke patients treated with a thrombolytic drug has just begun in China.
Current observations of nelonemdaz in acute ischemic stroke patients receiving recanalization therapies promises to open up a new era of neuroprotection therapy for the treatment of stroke.
Dr. Chang Gun Kim +82-2-70-4261-0786
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate23.10.2020 21:00:00 EEST | Press release
Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI’s own efforts to leverage science and innovation. Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) is the majority shareholder and PMIBV’s partner in Medicago. Among other things, PMIBV and MTPC will contribute additional funding to support Medicago’s efforts to develop a COVID-19 vaccine candidate. Medicago, a biopharmaceutical company headquartered in Quebec City, announced that it reached an agreement with Public Services and Procurement Canada (PSPC) to supply up to 76 million doses of its vaccine candidate for COVID-19, subject to Health Canada approval. Innovation, Science & Economic Development (ISED), another department
Fujikura Enters 5G mmWave Infrastructure Market With the Introduction of Industry’s Highest Performance, and Low Power Consumption Phased Array Antenna Module (PAAM)23.10.2020 11:00:00 EEST | Press release
Fujikura Ltd. (TOKYO:5803) (President & CEO: Masahiko Ito) today announced the introduction of industry’s most advanced and highly integrated Phased Array Antenna Module (PAAM) for 5G mmWave operating in 3GPP bands n257 (28 GHz), n258 (26 GHz) and n261 (27 GHz). The Fujikura PAAM is the industry’s highest performance PAAM targeting indoor and outdoor applications such as 5G mmWave Fixed Wireless Access (FWA), 5G mmWave Mobile Wireless Access (MWA), 5G mmWave wireless backhaul, and other emerging applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005099/en/ Fig.1 Block diagram of Fujikura PAAM. (Graphic: Business Wire) Key Differentiating Features of the Fujikura PAAM The Fujikura PAAM is a high performance phased array antenna module with a novel integrated antenna, and supports concurrent dual polarized beams in both transmission and reception (Fig.1). The PAAM integrates best-in-class mmWave-ICs developed i
VAAST Bikes Now Available in Europe23.10.2020 10:02:00 EEST | Press release
VAAST Bikes, a forward-thinking bicycle manufacturer known for its innovative Allite® Super Magnesium™ frames, has signed an agreement with German cycling-specialist retailer giant Internetstores (Fahrrad.de/Brügelmann.de/Bikester). Two of VAAST’s key bicycle models – including the gravel-ready all-road A/1 bike, and the urban U/1 – are now stocked at Internetstores’ eCommerce sites. Both VAAST models will be available to order online for delivery in fourteen locations across Europe via Fahrrad.de/Brügelmann.de in Germany and the partner site Bikester in 13 countries, including the UK, France, the Netherlands, Belgium, Switzerland, Austria, Poland, Denmark, Italy, Sweden, Norway, Finland and Spain. Customers in Germany can benefit from personal service in Fahrrad.de’s five stores and 190 local service partners, while eCommerce customers Europe-wide will be able to receive their new VAAST bicycle within just days of ordering online. VAAST’s unique position as the only bicycle manufactur
Mitsubishi Chemical Holdings Corporation: Notice Regarding Change in Representative Corporate Executive Officers23.10.2020 09:40:00 EEST | Press release
Mitsubishi Chemical Holdings Corporation (“MCHC”) (TOKYO: 4188) announced that, at the meeting of its Board of Directors held today, it resolved change of representative corporate executive officers as outlined below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022006285/en/ Jean-Marc Gilson (Photo: Business Wire) 1. Change in Representative Corporate Executive Officers (Appointed) Name: Jean-Marc Gilson Title: Representative Corporate Executive Officer President and Chief Executive Officer (Retiring) Name: Hitoshi Ochi Title: Representative Corporate Executive Officer President and Chief Executive Officer 2. Biographical Sketch of New Representative Corporate Executive Officer Refer to the appendix 3. Scheduled Date of Appointment April 1, 2021 4. Reason for the Change MCHC converted to a company with a nominating committee, etc. in June 2015. Since then, the Nominating Committee has carried out preparations to proper
MYAH Wins Prestigious Silmo D’Or Award23.10.2020 08:00:00 EEST | Press release
Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that its MYAH myopia and dry eye management device has won the 2020 Silmo D’Or Award in the Material/Equipment category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005242/en/ Topcon Healthcare announced today that its MYAH myopia and dry eye management device has won the 2020 Silmo D’Or Award. (Photo: Business Wire) The Silmo D’Or Awards are presented each year to recognize creativity in optical product design, innovation and technology. This year marked the 27th annual awards ceremony, which was held virtually and live streamed online on Saturday, October 3rd. The award committee was proud to recognize forward-thinking companies who have continued to launch products and propel the industry forward despite the global pandemic. MYAH came out on top in the Material/Equipment category and
ABB: Q3 2020 Results23.10.2020 07:46:00 EEST | Press release
“Third quarter revenues in all business areas were still dampened due to the impact of COVID-19, although a strong recovery in China and ongoing cost mitigation efforts supported a strong underlying performance. On the upside, the integration of GEIS and turnaround of Installation Products in Electrification is starting to bear fruit and Motion is performing robustly. Robotics and Industrial Automation, on the other hand, are taking more time to recover,” said Björn Rosengren, CEO of ABB. “We are pushing ahead with the decentralization of the group and the ongoing review of our portfolio, while carrying out our share buyback program as planned. We look forward to presenting further details on our strategic progress at our Capital Markets Day on November 19.” KEY FIGURES CHANGE CHANGE ($ millions, unless otherwise indicated) Q3 2020 Q3 2019 US$ Comparable 9M 2020 9M 2019 US$ Comparable Orders 6,109 6,688 -9% -8% 19,509 21,702 -10% -7% Revenues 6,582 6,892 -4% -4% 18,952 20,910 -9% -7% I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom